XenoPort, Inc announced that the European Patent Office (EPO) Opposition Division ruled that the European patent for the composition of matter of XP13512 (European Patent No. 1 404 324) is valid. This favourable decision means that XenoPort retains composition-of-matter protection on multiple forms of XP13512 molecules, and its patent continues to be valid in Austria, Belgium, Switzerland and Liechtenstein, Cyprus, Germany, Denmark, Spain, Finland, France, UK, Greece, Ireland, Italy, Luxembourg, Monaco, The Netherlands, Portugal, Sweden and Turkey until June 2022.
XP13512 is a new chemical entity that is being developed for restless legs syndrome, neuropathic pain and migraine prophylaxis. This investigational compound, also known as Horizant (gabapentin enacarbil) in the United States, is not presently marketed anywhere in the world.
XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.